Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meglumine Antimoniate Schemes for Mucosal Leishmaniasis
NCT01301937Phase 3Unknown
- Sponsor
- Fundação Oswaldo Cruz
- Start
- Oct 2008
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of meglumine antimoniate in mucocutaneous leishmaniasis (MCL) (2 arms), sponsored by Fundação Oswaldo Cruz. Primary endpoint: Initial therapeutic response (epithelialization and resolution of mucosal infiltration) at 150 days. Status: unknown.
02
Drugs
meglumine antimoniate
03
Conditions
mucocutaneous leishmaniasis (MCL)
Beyond the preview
Go deeper on NCT01301937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01301937.